AEROVATE THERAPEUTICS INC(NASDAQ:AVTE) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to AVTE. AVTE was compared to 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTE as it has an excellent financial health rating, but there are worries on the profitability. AVTE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

AVTE had negative earnings in the past year.

AVTE had a negative operating cash flow in the past year.

In the past 5 years AVTE always reported negative net income.

AVTE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -86.68%, AVTE is not doing good in the industry: 72.34% of the companies in the same industry are doing better.

AVTE's Return On Equity of -91.10% is in line compared to the rest of the industry. AVTE outperforms 48.40% of its industry peers.

		Industry Rank	Sector Rank
ROA	-86.68%
ROE	-91.1%
ROIC	N/A

ROA(3y)-61.34%

ROA(5y)-80.96%

ROE(3y)-66.92%

ROE(5y)-110.13%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVTE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AVTE has more shares outstanding than it did 1 year ago.

AVTE has more shares outstanding than it did 5 years ago.

There is no outstanding debt for AVTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 5.98 indicates that AVTE is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 5.98, AVTE belongs to the top of the industry, outperforming 82.98% of the companies in the same industry.

AVTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	5.98

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 20.93 indicates that AVTE has no problem at all paying its short term obligations.

The Current ratio of AVTE (20.93) is better than 95.21% of its industry peers.

AVTE has a Quick Ratio of 20.93. This indicates that AVTE is financially healthy and has no problem in meeting its short term obligations.

AVTE has a Quick ratio of 20.93. This is amongst the best in the industry. AVTE outperforms 95.21% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	20.93
Quick Ratio	20.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AVTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.28%, which is quite good.

EPS 1Y (TTM)15.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.32%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVTE will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.10% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y74.29%

EPS Next 2Y-1.49%

EPS Next 3Y19.52%

EPS Next 5Y12.1%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AVTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVTE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AVTE's earnings are expected to grow with 19.52% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.49%

EPS Next 3Y19.52%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AVTE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AEROVATE THERAPEUTICS INC

NASDAQ:AVTE (4/28/2025, 8:00:00 PM)

After market: 2.6505 -0.03 (-1.1%)

2.68

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-25 2025-03-25/amc

Earnings (Next)05-12 2025-05-12/amc

Inst OwnersN/A

Inst Owner Change6.08%

Ins OwnersN/A

Ins Owner Change0%

Market Cap77.69M

Analysts48.89

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)15.62%

Min EPS beat(2)5.75%

Max EPS beat(2)25.49%

EPS beat(4)2

Avg EPS beat(4)5.57%

Min EPS beat(4)-6.37%

Max EPS beat(4)25.49%

EPS beat(8)2

Avg EPS beat(8)0.32%

EPS beat(12)3

Avg EPS beat(12)-5.75%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)18.64%

EPS NY rev (1m)10.65%

EPS NY rev (3m)10.65%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.02
P/tB	1.02
EV/EBITDA	N/A

EPS(TTM)-2.44

EYN/A

EPS(NY)-0.63

Fwd EYN/A

FCF(TTM)-2.46

FCFYN/A

OCF(TTM)-2.46

OCFYN/A

SpS0

BVpS2.64

TBVpS2.64

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-86.68%
ROE	-91.1%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-61.34%

ROA(5y)-80.96%

ROE(3y)-66.92%

ROE(5y)-110.13%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	20.93
Quick Ratio	20.93
Altman-Z	5.98

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)15.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.32%

EPS Next Y74.29%

EPS Next 2Y-1.49%

EPS Next 3Y19.52%

EPS Next 5Y12.1%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y8.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-25.08%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-25.39%

OCF growth 3YN/A

OCF growth 5YN/A

AEROVATE THERAPEUTICS INC (AVTE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens